New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
Rev. Soc. Bras. Med. Trop
;
48(3): 235-242, May-Jun/2015. tab, graf
Artigo
em Inglês
| LILACS
| ID: lil-749870
ABSTRACT
Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Anfotericina B
/
Sistemas de Liberação de Medicamentos
/
Leishmaniose Visceral
/
Antiprotozoários
Limite:
Animais
/
Humanos
Idioma:
Inglês
Revista:
Rev. Soc. Bras. Med. Trop
Assunto da revista:
Medicina Tropical
Ano de publicação:
2015
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Universidade Federal de Minas Gerais/BR
Similares
MEDLINE
...
LILACS
LIS